Noor Zaheer Ahmed

Dr. Noor Zaheer Ahmed

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2021 in Journal of Complementary and Integrative Medicine
Verified
Journal Article
Closed access
NANoor Zaheer Ahmed
Noor Zaheer Ahmed
NANoman Anwar
Noman Anwar
SBShahida Begum
Shahida Begum
APAthar Parvez
Athar Parvez
RERadhakrishnan Ezhil
Radhakrishnan Ezhil
NANighat Anjum
Nighat Anjum
Objectives: Low back pain is the most widespread musculoskeletal ailment and a common cause of disability worldwide. Conventional medicine typically treats low back pain with a combination of physical therapy; activity modification and rest; pain-relieving and anti-inflammatory medications which are associated with huge socioeconomic implications and adverse drug reactions. In contrast Ḥijāma, Dalk and Bukhūr are ancient medical techniques recommended in the management of musculoskeletal disorders with little or no adverse effects. To evaluate the safety and effectiveness of Ḥijāma bi’l Shart (wet cupping), followed by Dalk (Massage) with Roghan Dafli and Bukhūr (medicated steam) with Tukhm Soya ( Anethum graveolens Linn) in patients of Waja al-Zahr (Non-specific Low back pain). Methods: Patients of either gender in the age group of 18–50 years with low back pain persisting for four weeks or more as chief complaint were recruited in the trial. The study was GCP compliant. The duration of the protocol therapy carried out was 14 days. Results: Ninty two patients of NSLBP were screened, of which 34 who fulfilled the inclusion criteria and were willing to participate in the study were recruited. Three participants were lost to follow-ups due to personal reasons and 31 patients completed the trial during the study period. Overall therapeutic response observed in this study was 97% while 3% of the patients did not respond to intervention. Conclusions: The study findings imply that there is a credible evidence to ensure that the regimens intervened are safe and effective in ameliorating the symptoms of Waja al-Zahr .

15 August 2021 in Journal of Drug Delivery and Therapeutics
Verified
Journal Article
Open access
PDF file
NANoor Zaheer Ahmed
Noor Zaheer Ahmed
DGDicky John Davis G
Dicky John Davis G
NANoman Anwar
Noman Anwar
AKAsim Ali Khan
Asim Ali Khan
RMRam Pratap Meena
Ram Pratap Meena
MDMeera Devi
Meera Devi
COVID-19 was originated in Wuhan, China, in December 2019 and has been declared a pandemic disease by WHO. The number of infected cases continues unabated and so far, no specific drug approved for targeted therapy. Hence, there is a need for drug discovery from traditional medicine. Tiryaq-e-Wabai is a well-documented formulation in Unani medicine for its wide use as prophylaxis during epidemics of cholera, plague and other earlier epidemic diseases. The objective of the current study is to generate in-silico evidence and evaluate the potency of Tiryaq-e-Wabai against SARS-CoV-2 spike (S) glycoprotein and main protease (3CLpro). The structures of all phytocompounds used in this study were retrieved from PubChem database and some were built using Marvin Sketch. The protein structure of the SARS-CoV-2 S glycoprotein and 3CLpro was retrieved from the PDB ID: 6LZG and 7BQY respectively. AutoDock Vina was used to predict top ranking poses with best scores. The results of the molecular docking showed that phytocompounds of Tiryaq-e-Wabai exhibited good docking power with spike glycoprotein and 3CLpro. Among tested compounds Crocin from Zafran and Aloin A from Sibr showed strong binding to spike glycoprotein and 3CLpro respectively. Molecular dynamics simulation confirmed the stability of the S glycoprotein-Crocin and 3CLpro-Aloin A complexes. The Unani formulation Tiryaq-e-Wabai has great potential to inhibit the SARS-CoV-2, which have to be substantiated with further in-vitro and in-vivo studies. Keywords: In-silico study, SARS-CoV-2, Tiryaq-e-Wabai, Unani formulation, Crocin, Aloin A

15 November 2022 in Journal of Drug Delivery and Therapeutics
Verified
Journal Article
Open access
PDF file
NANoman Anwar
Noman Anwar
NANoor Zaheer Ahmed
Noor Zaheer Ahmed
SBShahida Begum
Shahida Begum
AAAthar Parvez Ansari
Athar Parvez Ansari
AVAmmu Jayanthi Viswanathan
Ammu Jayanthi Viswanathan
Objectives: Anorexia is one among the most prevalent conditions triggering malnutrition, drastic weight loss and serious health issues in people especially older adults. Habb-e-Hilteet is commonly prescribed Unani pharmacopoeial formulation for anorexia. However, no scientific data is available as to its safety and efficacy. The current study assessed the appetite-inducing effect and safety of Habb-e-Hilteet in Ḍu‘f al-Ishtihā (anorexia) patients. Methods: An open prospective clinical trial was carried out in 95 clinically diagnosed anorexia patients of either gender (19-65 yrs old). The study was approved by Institutional ethic committee and conducted in accordance with the GCP guidelines. Habb-e-Hilteet, 1 pill (500mg) was administered orally in patients twice daily for 14 days. The safety of the formulation was assessed by important pathological and biochemical indices and monitoring adverse events. The efficacy was assessed on the basis of improvement in the Simplified Nutritional Appetite Questionnaire (SNAQ) score. Results: Out of 95 patients recruited, 78 completed the trial and 17 patients lost to follow-up. The mean age of patients was 29.8 yrs, with the majority (59.0%) being female. Overall therapeutic response was found to be 96%. A significant (P<0.05) increase in the mean SNAQ score was observed after 7 and 14 days of treatment when compared to baseline. No significant difference before and after treatment was observed in pathological and biochemical indices. No adverse events were reported during the entire study period. Conclusion: The study results indicate that Habb-e-Hilteet could be a viable treatment option for anorexia with no safety concerns. Keywords: Ḍu‘f al-Ishtihā; Buṭlān al-Shahwa; Anorexia; Habb-e-Hilteet; Unani pharmacopoeal formulation.

15 July 2021 in Journal of Drug Delivery and Therapeutics
Verified
Journal Article
Open access
PDF file
NANoman Anwar
Noman Anwar
NANoor Zaheer Ahmed
Noor Zaheer Ahmed
SBShehnaz Begum
Shehnaz Begum
The current pandemic caused by SARS-CoV-2 has led to a massive change in every aspect of our lives. It has grossly affected the healthcare system, business and world trade, disruption of movement and supply of essential goods and has crippled the global economy. Although few vaccines have been approved for the control of disease, targeted therapy options for this virulent disease still remain limited and elusive. Exhaustive search for potent therapeutic candidate is in progress, for which herbal armory are also being explored. Medicinal plants and their products play a vital role in alleviating various diseases and have been reported to exhibit a wide range of biological activities. Plant-based drugs with antiviral, anti-inflammatory and immunomodulotry activities were hypothetically considered as potential drugs to prevent and mitigate the prevailing situation caused by SARS-CoV-2. Arq Ajīb ‘a Unani formulation’ presents compelling approach in treating numerous diseases. The ingredients of Arq Ajīb and their phytocompounds have been reported for wide-ranging pharmaco-biological activities including antiviral, anti-inflammatory, immunomodulotry, anti-allergic, antitussive and bronchodilatory activities. Scientific data available on the formulation ingredients and their phytocompounds indicates that the formulation may have a significant role in augmenting the immune status of individual, protecting them from infection and providing symptomatic relief to patients affected with COVID-19. Hence, it may be considered as a potential drug for the development of novel therapeutic candidate for SARS-CoV-2 infection. This multi-faceted review highlights the therapeutic significance and pharmacological actions of Arq Ajīb and its ingredients to demonstrate the plausible role of the formulation in combating COVID-19. Keywords: Arq Ajīb, COVID-19, Pudina, Ajwain, Camphor, Unani formulation

19 May 2020 in Journal of Complementary and Integrative Medicine
Verified
Journal Article
Closed access
PDF file
NANoor Zaheer Ahmed
Noor Zaheer Ahmed
KAKabiruddin Ahmed
Kabiruddin Ahmed
NANoman Anwar
Noman Anwar
RERadhakrishnan Ezhil
Radhakrishnan Ezhil
NANighat Anjum
Nighat Anjum
AKAsim Ali Khan
Asim Ali Khan
Background: Hasat-ul Kilya (Nephrolithiasis) is one of the most common chronic conditions and has been known to the mankind since antiquity. The incidence is increasing globally with geographic, racial and gender variation in its occurrence. Medical management of Nephrolithiasis still poses a considerable challenge for modern medical practice. Unani drugs possessing lithotriptic activity are not only cost effective but also have least side effects. Safūf Hajar-al Yahūd has been used since long for the treatment of Hasat-ul Kilya (Nephrolithiasis) but no documentary evidence based on scientific parameters as to its safety and efficacy are available. Objective: To validate the safety and efficacy of Safūf Hajar-al Yahūd in the treatment of Hasat-ul Kilya . Methodology: An open prospective clinical trial was carried out on 107 subjects of renal calculi of 3–7 mm diameter diagnosed by Ultrasonogram-KUB (USG-KUB). Subjects were evaluated by clinical history & examination, laboratory investigations followed by USG-KUB for confirmation. The safety was assessed by reporting of adverse events and by pathological and biochemical investigations. Assessment of efficacy was based on improvement observed in VAS score and expulsion/reduction of stone size as detected by USG-KUB. Results: Substantial reduction (53%) in the size of calculi confirmed by USG-KUB and considerable lowering of VAS score (75%) were observed with the active intervention in majority of the cases Conclusion: The trial has revealed that the Unani pharmacopoeal formulation Safūf Hajar-al Yahūd was well tolerated and has the therapeutic potential in the reduction and expulsion of renal calculi.
1

17 December 2024 in Next Research
Verified
Journal Article
Closed access
AAAthar Parvez Ansari
Athar Parvez Ansari
MAMary Shamya Arokiarajan
Mary Shamya Arokiarajan
JCJohn Christopher
John Christopher
NANoman Anwar
Noman Anwar
NANoor Zaheer Ahmed
Noor Zaheer Ahmed
KAK. Kabiruddin Ahmed
K. Kabiruddin Ahmed